Follow-up of positive cases of lymphatic filariasis after Transmission Assessment Survey (TAS) 2 and TAS 3 in Burkina Faso
Identify the sampling strategy for tracking positive cases after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of active transmission, while saving program resources
A pilot study to identify meaningful and measurable targets for detecting the control of schistosomiasis-related morbidity in Africa. The overall study is designed to answer the following primary evaluation questions:
- What are the infection levels of Schistosoma mansoni and S. haematobium below which there is little, or no, detectable schistosomiasis-associated morbidity?
- What are the optimal morbidity markers for S. mansoni and S. haematobium?
- What are the optimal species-specific morbidity goals for which schistosomiasis control programs should be aiming?
Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt
What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?
Coverage Evaluation Survey and Supervisor's Coverage Tool Implementation in Kenya for Triple Drug Therapy
Coverage Evaluation Survey
Is coverage, or a combination of coverage and systematic non-compliance, more effective than a diagnostic tool at predicting when it is safe to stop triple drug therapy?
Supervisor's Coverage Tool
Is the use of the SCT during IDA feasible to implement at the sub-county scale and does it lead to increased coverage?
Whole genome sequencing of ocular Chlamydia trachomatis in Amhara region, Ethiopia, an area with persistent hyperendemic trachoma.
This study will address the characteristics of the ocular chlamydia trachomatis population structures within Amhara, a setting which has experienced repeated rounds of antibiotic for trachoma, and whether those circulating populations are different than known sequenced strains.
Field friendly biometry to ease cohort studies in resource-limited settings: application to the Test and Treat for onchocerciasis project in Central Cameroon
Can a biometric recognition system, in the context of “Test and Treat”, facilitate individual follow-up by linking participant data at different time-points?
Would the same programmatic decisions for Oncho Elimination Mapping be made based off of the Ov16 rapid diagnostic test results as compared to the Ov16 SD ELISA results?
To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.